The institute has developed a chimeric immunotoxin to combat cancer cells.
Print version |
30 09.2025
The Nizhny Novgorod Research Institute of Epidemiology and Microbiology named after Academician I.N. Blokhina has received a patent for an innovative invention that could change the approach to cancer treatment.
|
The chimeric immunotoxin is based on a rotavirus protein, which has demonstrated high efficacy against cancer cells, particularly those with a unique marker, mucin 1 (MUC1).
The immunotoxin consists of two key components:
An antibody that binds to MUC1 on the surface of cancer cells.
A peptide derived from the rotavirus protein promotes the destruction of these cells.
Binding of the immunotoxin to cancer cells disrupts cell division and triggers their death through apoptosis. This development is intended to provide more effective and less traumatic cancer treatment for patients.
